带状疱疹是由人体内潜伏的水痘-带状疱疹病毒复发感染导致的感染性皮肤病，其发病率和严重程度与年龄增长以及免疫功能低下有关。感染水痘-带状疱疹病毒的人群在儿童期发病表现为水痘，成年之后发病表现为带状疱疹。我国每年有近300万成年人罹患带状疱疹，却缺乏有效的治疗手段。目前全球已上市的带状疱疹疫苗主要是美国默沙东公司的Zostavax以及英国葛兰素史克公司的Shingrix。此文就带状疱疹的流行病学及国内外相关带状疱疹疫苗的研究进展进行综述，以期为我国带状疱疹疾病的预防及疫苗的开发研究提供理论参考。

Herpes zoster (HZ) is an infectious skin disease resulting from latent varicella-zoster virus (VZV) recurrent infection in humans, and its incidence and severity are associated with advancing age as well as immunocompromise. Persons infected with VZV present chickenpox in childhood and HZ in adulthood. Almost 3 million adults suffer from HZ disease every year in China, but there is no effective treatment. Zostavax of MSD and Shingrix of GlaxoSmithKline are the main types of HZ vaccine available worldwide. This study reviews the epidemiology of HZ disease and the progress of HZ vaccines at home and abroad, to provide a theoretical reference for the prevention of HZ disease and the development of vaccines.